On Invalid Date, Ars Pharmaceuticals (NASDAQ: SPRY) reported Q4 2023 earnings per share (EPS) of -$0.07, up 66.67% year over year. Total Ars Pharmaceuticals earnings for the quarter were -$7.17 million. In the same quarter last year, Ars Pharmaceuticals's earnings per share (EPS) was -$0.21.
As of Q1 2024, Ars Pharmaceuticals's earnings has grown year over year. Ars Pharmaceuticals's earnings in the past year totalled -$54.37 million.
What is SPRY's earnings date?
Ars Pharmaceuticals's earnings date is Invalid Date. Add SPRY to your watchlist to be reminded of SPRY's next earnings announcement.
What was SPRY's revenue last quarter?
On Invalid Date, Ars Pharmaceuticals (NASDAQ: SPRY) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Ars Pharmaceuticals's revenue was $0.00.
What was SPRY's revenue growth in the past year?
As of Q1 2024, Ars Pharmaceuticals's revenue has grown -97.72% year over year. This is 263.33 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Ars Pharmaceuticals's revenue in the past year totalled $30.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.